Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 8/20 | 0.66 |
| ▸ | AKR1C2 | P52895 | 8/20 | 0.66 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.54 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.54 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.54 |
| ▸ | THPO | P40225 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1760202 | 1.00 | AKR1C3 (0.66) | AKR1C3AKR1C2PTGS1SMN1; SMN2MAPT | |
| SCHEMBL27483949 | 0.88 | CES2 (0.55) | AKR1C3AKR1C2SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL377074 | 0.85 | AURKA (0.57) | AKR1C3AKR1C2CES2ACP3NPSR1 | |
| SCHEMBL14983791 | 0.85 | CES2 (0.53) | AKR1C3AKR1C2SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL7357616 | 0.84 | PTGS1 (0.56) | AKR1C3AKR1C2PTGS1SMN1; SMN2MAPT | |
| SCHEMBL28423546 | 0.84 | CES2 (0.60) | AKR1C3AKR1C2PTGS1SMN1; SMN2MAPT | |
| SCHEMBL4445388 | 0.83 | CES2 (0.55) | AKR1C3AKR1C2SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL5791155 | 0.83 | AKR1C3 (0.70) | AKR1C3AKR1C2PTGS2 | |
| SCHEMBL6270587 | 0.83 | AKR1C3 (0.63) | AKR1C3AKR1C2PTGS2 | |
| SCHEMBL3145951 | 0.83 | PTGS1 (0.54) | AKR1C3AKR1C2PTGS1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11697636-B2 | Substituted benzamides | HOFFMANN-LA ROCHE INC. (US) | 2023-07-11 | — | — | US | disclosed |
| EP-3187490-B1 | SUBSTITUTED BENZAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2022-04-06 | — | — | EP | disclosed |
| US-20210061760-A1 | SUBSTITUTED BENZAMIDES | HOFFMANN LA ROCHE (US) | 2021-03-04 | — | — | US | disclosed |
| US-20200048194-A1 | SUBSTITUTED BENZAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2020-02-13 | — | — | US | disclosed |
| EP-3187490-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2017-07-05 | — | — | EP | disclosed |
| US-9452980-B2 | Substituted benzamides | HOFFMANN-LA ROCHE INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20160264596-A1 | SUBSTITUTED BENZAMIDES | HOFFMANN-LA ROCHE INC. | 2016-09-15 | — | — | US | disclosed |
| CN-105254623-A | SUBSTITUTED BENZAMIDES | HOFFMANN LA ROCHE | 2016-01-20 | — | — | CN | disclosed |
| EP-2516392-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-10-31 | — | — | EP | disclosed |
| CN-102686563-A | Substituted benzamide derivatives | HOFFMANN LA ROCHE | 2012-09-19 | — | — | CN | disclosed |
| WO-2011076678-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-30 | — | — | WO | disclosed |
| US-20110152245-A1 | SUBSTITUTED BENZAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264596-A1 | SUBSTITUTED BENZAMIDES | TAAR1, TAAR5, NPY1R | AKR1C3 515/4885AKR1C2 399/4885PTGS1 2539/4885 |
| US-20210061760-A1 | SUBSTITUTED BENZAMIDES | TAAR1, TAAR5, NPY1R | AKR1C3 515/4885AKR1C2 399/4885PTGS1 2539/4885 |
| US-20110152245-A1 | SUBSTITUTED BENZAMIDES | TAAR1, TAAR5, NPY1R | AKR1C3 515/4885AKR1C2 399/4885PTGS1 2539/4885 |
| US-20200048194-A1 | SUBSTITUTED BENZAMIDES | TAAR1, TAAR5, NPY1R | AKR1C3 515/4885AKR1C2 399/4885PTGS1 2539/4885 |
| US-11697636-B2 | Substituted benzamides | TAAR1, TAAR5, NPY1R | AKR1C3 515/4885AKR1C2 399/4885PTGS1 2539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.